The upgrade includes the installation of complex bottling and labeling equipment, intended for early-stage clinical production services. This development is expected to boost the delivery of pharmaceutical products to clinical trial sites, offering broad access benefits to Lonza consumers in the pharmaceutical and biotechnology sectors.
The new device is designed to handle counterfeit dosage forms, especially powder-filled tablets and capsules. The machines have complex functions to detect defects in dosage forms, ensuring that only the highest quality products are packaged and labeled. The bottling procedure is comprehensive and includes bottle cleaning, filling, capping, sealing, and labeling, all critical steps in preparing products for early-stage clinical trials.
This expansion is part of Lonza’s broader strategy to meet the desires of the pharmaceutical industry from early progression to commercialization. With those new capabilities, Lonza is better able to serve its customers, i. e. , those who push their drug applicants through Phase 1 and Phase 2. clinical trials.
The Bend facility is a critical hub in Lonza’s global network and serves as the company’s center of excellence for bioavailability improvement and inhalation delivery systems. For more than forty-five years, the Bend team has been at the forefront of addressing demanding solubility situations and modulating pharmacokinetics to meet the expressed desires of target product profiles. Currently, the facility supports more than 80 active programs, making it the cornerstone of Lonza’s small molecule production and progression operations.
The addition of bottling and labeling capabilities aligns with Lonza’s ongoing commitment to expanding its service offering to meet the changing desires of its customers. As drug progression timelines become tighter, the ability to temporarily and successfully package and deliver clinical trial documents is more critical than ever. The new device at the Bend site allows Lonza to better meet those demands, providing more streamlined and integrated service to its customers.
This update is especially favorable for early-stage corporations that want rapid and reliable clinical production to advance their drug applicants into the initial phases of testing. By reducing the time required to prepare and deliver testing materials, Lonza is helping its consumers succeed at critical milestones. faster, which can be decisive in the competitive pharmaceutical landscape.
Lonza’s enhanced features at the Bend site are expected to appeal to a wider diversity of customers, adding emerging biotech corporations and established pharmaceutical corporations to power its clinical programs. The investment in new bottling and labeling apparatus not only strengthens Lonza’s portfolio of services, but also strengthens its position as a trusted spouse in the global drug progression process.
More Promotional Features